Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities

Genes Dev. 2019 Oct 1;33(19-20):1295-1318. doi: 10.1101/gad.329771.119.

Abstract

An incomplete view of the mechanisms that drive metastasis, the primary cause of cancer-related death, has been a major barrier to development of effective therapeutics and prognostic diagnostics. Increasing evidence indicates that the interplay between microenvironment, genetic lesions, and cellular plasticity drives the metastatic cascade and resistance to therapies. Here, using melanoma as a model, we outline the diversity and trajectories of cell states during metastatic dissemination and therapy exposure, and highlight how understanding the magnitude and dynamics of nongenetic reprogramming in space and time at single-cell resolution can be exploited to develop therapeutic strategies that capitalize on nongenetic tumor evolution.

Keywords: MITF; cancer; melanoma; microenvironment; phenotypic plasticity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cell Plasticity*
  • Drug Resistance, Neoplasm
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Melanoma / physiopathology*
  • Melanoma / therapy
  • Microphthalmia-Associated Transcription Factor / genetics
  • Microphthalmia-Associated Transcription Factor / metabolism
  • Neoplasm Metastasis / physiopathology*
  • Neoplastic Stem Cells / cytology
  • Phenotype
  • Tumor Microenvironment

Substances

  • Microphthalmia-Associated Transcription Factor